| |
 |
Kimberly O. Cameron Patents |
|
Inventor: Cameron; Kimberly O.
Address: East Lyme, CT
No. of patents: 28
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| RE39558 |
5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating |
April 10, 2007 |
| Compounds of this formula ##STR00001## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease. |
| 7414071 |
Methods of treatment with selective EP4 receptor agonists |
August 19, 2008 |
| The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP.sub.4 receptor agonist of |
| 7358242 |
Tetraazabenzo[e]azulene derivatives and analogs thereof |
April 15, 2008 |
| This invention relates to CCK-A agonists of Formula (I) ##STR00001## wherein R.sup.1-R.sup.4, A, B, X, D, E and G are as defined in the specification, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and composit |
| 7265104 |
Tetraazabenzo[e]azulene derivatives and analogs thereof |
September 4, 2007 |
| This invention relates to CCK-A agonists of Formula (I) ##STR00001## wherein R.sup.1-R.sup.4, A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and composi |
| 7192979 |
EP4 receptor selective agonist in the treatment of osteoporosis |
March 20, 2007 |
| This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, ##STR00001## wherein R.sup.2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is al |
| 7053212 |
Acyclic amide and sulfonamide ligands for the estrogen receptor |
May 30, 2006 |
| The present invention provides estrogen receptor (ER) ligands of structural formula (I) ##STR00001## the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the prodrugs, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.s |
| 6998423 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
February 14, 2006 |
| Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis. |
| 6852863 |
Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-ac eti |
February 8, 2005 |
| The present invention relates to metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-ac etic acid. |
| 6756388 |
Benzothiophenes and related compounds as estrogen agonists |
June 29, 2004 |
| The invention is a compound of Formula (I): ##STR1##wherein R is --OH, R.sup.1 is --OH, R.sup.2 is --H, n is 2 or 3 and X is sulfur, or a pharmaceutically acceptable salt of a compound having Formula (1), or a pharmaceutical composition comprising a compound having Formula ( |
| 6747054 |
EP4 receptor selective agonists in the treatment of osteoporosis |
June 8, 2004 |
| This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, ##STR1##wherein R.sup.2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also dir |
| 6737437 |
EP4 receptor selective agonists in the treatment of osteoporosis |
May 18, 2004 |
| This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associ |
| 6649657 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
November 18, 2003 |
| Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis. |
| 6642266 |
EP4 receptor selective agonists in the treatment of osteoporosis |
November 4, 2003 |
| This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associ |
| 6608203 |
Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
August 19, 2003 |
| This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compounds. |
| 6552067 |
EP4 receptor selective agonists in the treatment of osteoporosis |
April 22, 2003 |
| This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, ##STR1##wherein R.sup.2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also dir |
| 6531485 |
Prostaglandin agonists |
March 11, 2003 |
| This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders |
| 6498172 |
Prostaglandin agonists and their use to treat bone disorders |
December 24, 2002 |
| This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders |
| 6492412 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
December 10, 2002 |
| Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis. |
| 6441193 |
Estrogen agonists/antagonists |
August 27, 2002 |
| Compounds of this formula ##STR1##are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease. |
| 6426359 |
Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin |
July 30, 2002 |
| This invention relates to the use of EP2 receptor subtype selective prostaglandin E2 agonists to augment bone mass including the prevention and treatment of skeletal disorders in mammals, including humans. |
| 6376502 |
Osteoporosis compounds |
April 23, 2002 |
| This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders |
| 6344485 |
Method for treating glaucoma |
February 5, 2002 |
| Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma. |
| 6288120 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
September 11, 2001 |
| Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits usef |
| 6204286 |
Estrogen agonists/antagonists |
March 20, 2001 |
| Compounds of the formula: ##STR1##are disclosed useful for treating osteoporosis, obesity, breast cancer, endometriosis, cardiovascular disease and prostatic disease. Substituents A, B, E, D, Z1, G, Y and e have the same meaning as defined in the specification. |
| 6153622 |
Estrogen agonists/antagonists |
November 28, 2000 |
| Compounds of this formula ##STR1## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease. |
| 6124314 |
Osteoporosis compounds |
September 26, 2000 |
| This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders |
| 5703108 |
Bone deposition by certain prostaglandin agonists |
December 30, 1997 |
| Methods for the treatment of bone disorders utilizing certain prostaglandin agonists/antagonists. |
| 5552412 |
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating o |
September 3, 1996 |
| Compounds of this formula ##STR1## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease. |
|
|
|
